Top

Published in:

01-08-2018 | Research Paper

Genetics of metastasis: melanoma and other cancers

Authors: Noel Turner, Olivia Ware, Marcus Bosenberg

Published in: Clinical & Experimental Metastasis | Issue 5-6/2018

Abstract

Melanoma is a malignant neoplasm of melanocytes that accounts for the majority of skin cancer deaths despite comprising less than 5% of all cutaneous malignancies. Its incidence has increased faster than that of any other cancer over the past half-century and the annual costs of treatment in the United States alone have risen rapidly. Although the majority of primary melanomas are cured with local excision, metastatic melanoma historically carries a grim prognosis, with a median survival of 9 months and a long-term survival rate of 10%. Given the urgent need to develop treatment strategies for metastatic melanoma and the explosion of genetic technologies over the past 20 years, there has been extensive research into the genetic alterations that cause melanocytes to become malignant. More recently, efforts have focused on the genetic changes that drive melanoma metastasis. This review aims to summarize the current knowledge of the genetics of primary cutaneous and ocular melanoma, the genetic changes associated with metastasis in melanoma and other cancer types, and non-genetic factors that may contribute to metastasis.

Clark WH Jr, Elder DE, Van Horn M (1986) The biologic forms of malignant melanoma. Hum Pathol 17(5):443–450PubMedCrossRef

Arrington JH 3rd et al (1977) Plantar lentiginous melanoma: a distinctive variant of human cutaneous malignant melanoma. Am J Surg Pathol 1(2):131–143PubMedCrossRef

Pandiani C et al (2017) Focus on cutaneous and uveal melanoma specificities. Genes Dev 31(8):724–743PubMedPubMedCentralCrossRef

Vazquez Vde L et al (2016) Molecular profiling, including TERT promoter mutations, of acral lentiginous melanomas. Melanoma Res 26(2):93–99PubMedCrossRef

Merkel EA, Gerami P (2017) Malignant melanoma of sun-protected sites: a review of clinical, histological, molecular features. Lab Invest 97(6):630–635PubMedCrossRef

Kim JY et al (2014) Acral lentiginous melanoma: indolent subtype with long radial growth phase. Am J Dermatopathol 36(2):142–147PubMedCrossRef

Barnhill RL et al (1996) Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer 78(3):427–432PubMedCrossRef

Curtin JA et al (2005) Distinct sets of genetic alterations in melanoma. New Engl J Med 353(20):2135–2147PubMedCrossRef

Lawrence MS et al (2013) Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499(7457):214–218PubMedPubMedCentralCrossRef

10.

Hodis E et al (2012) A landscape of driver mutations in melanoma. Cell 150(2):251–263PubMedPubMedCentralCrossRef

11.

Harris RS (2013) Cancer mutation signatures, DNA damage mechanisms, and potential clinical implications. Genome Med 5(9):87PubMedPubMedCentralCrossRef

12.

Cheng KC et al (1992) 8-Hydroxyguanine, an abundant form of oxidative DNA damage, causes G—T and A—C substitutions. J Biol Chem 267(1):166–172CrossRefPubMed

13.

Network TCGA (2015) Genomic classification of cutaneous melanoma. Cell 161(7):1681–1696CrossRef

14.

Davies H et al (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892):949–954CrossRefPubMed

15.

Avruch J et al (2001) Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade. Recent Prog Horm Res 56:127–155PubMedCrossRef

16.

Krauthammer M et al (2012) Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet 44(9):1006–1014PubMedPubMedCentralCrossRef

17.

Nikolaev SI et al (2011) Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet 44(2):133–139PubMedCrossRef

18.

Bauer J et al (2007) Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. J Invest Dermatol 127(1):179–182PubMedCrossRef

19.

Pollock PM et al (2003) High frequency of BRAF mutations in nevi. Nat Genet 33(1):19–20PubMedCrossRef

20.

Dhomen N et al (2009) Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 15(4):294–303PubMedCrossRef

21.

Vredeveld LC et al (2012) Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev 26(10):1055–1069PubMedPubMedCentralCrossRef

22.

Wu H, Goel V, Haluska FG (2003) PTEN signaling pathways in melanoma. Oncogene 22(20):3113–3122PubMedCrossRef

23.

Mirmohammadsadegh A et al (2006) Epigenetic silencing of the PTEN gene in melanoma. Cancer Res 66(13):6546–6552PubMedCrossRef

24.

Shull AY et al (2012) Novel somatic mutations to PI3K pathway genes in metastatic melanoma. PLoS ONE 7(8):e43369PubMedPubMedCentralCrossRef

25.

Davies MA et al (2008) A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer 99(8):1265–1268PubMedPubMedCentralCrossRef

26.

Halaban R (2015) RAC1 and melanoma. Clin Ther 37(3):682–685PubMedCrossRef

27.

Vu HL et al (2015) RAC1 P29S regulates PD-L1 expression in melanoma. Pigment Cell Melanoma Res 28(5):590–598PubMedPubMedCentralCrossRef

28.

Berger MF et al (2012) Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 485(7399):502–506PubMedPubMedCentralCrossRef

29.

Bennett DC (2008) How to make a melanoma: what do we know of the primary clonal events? Pigment Cell Melanoma Res 21(1):27–38PubMedCrossRef

30.

Shtivelman E et al (2014) Pathways and therapeutic targets in melanoma. Oncotarget 5(7):1701–1752PubMedPubMedCentralCrossRef

31.

Reddy BY, Miller DM, Tsao H (2017) Somatic driver mutations in melanoma. Cancer 123(S11):2104–2117PubMedCrossRef

32.

Huang FW et al (2013) Highly recurrent TERT promoter mutations in human melanoma. Science 339(6122):957–959PubMedPubMedCentralCrossRef

33.

Horn S et al (2013) TERT promoter mutations in familial and sporadic melanoma. Science 339(6122):959–961CrossRefPubMed

34.

Bell RJ et al (2015) Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. Science 348(6238):1036–1039PubMedPubMedCentralCrossRef

35.

Garraway LA et al (2005) Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436(7047):117–122CrossRefPubMed

36.

Hartman ML, Czyz M (2015) MITF in melanoma: mechanisms behind its expression and activity. Cell Mol Life Sci 72(7):1249–1260PubMedCrossRef

37.

Chin L, Garraway LA, Fisher DE (2006) Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev 20(16):2149–2182CrossRefPubMed

38.

Prickett TD et al (2014) Somatic mutation of GRIN2A in malignant melanoma results in loss of tumor suppressor activity via aberrant NMDAR complex formation. J Invest Dermatol 134(9):2390–2398PubMedPubMedCentralCrossRef

39.

Prickett TD et al (2011) Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. Nat Genet 43(11):1119–1126PubMedPubMedCentralCrossRef

40.

Neto A, Ceol CJ (2018) Melanoma-associated GRM3 variants dysregulate melanosome trafficking and cAMP signaling. Pigment Cell Melanoma Res 31(1):115–119PubMedCrossRef

41.

Gembarska A et al (2012) MDM4 is a key therapeutic target in cutaneous melanoma. Nat Med 18(8):1239–1247PubMedCrossRef

42.

Stefansson B, Brautigan DL (2007) Protein phosphatase PP6 N terminal domain restricts G1 to S phase progression in human cancer cells. Cell Cycle 6(11):1386–1392PubMedCrossRef

43.

Valentin-Vega YA et al (2016) Cancer-associated DDX3X mutations drive stress granule assembly and impair global translation. Sci Rep 6:25996PubMedPubMedCentralCrossRef

44.

Dutton-Regester K et al (2014) A highly recurrent RPS27 5′UTR mutation in melanoma. Oncotarget 5(10):2912–2917PubMedPubMedCentralCrossRef

45.

Bastian BC et al (1998) Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res 58(10):2170–2175PubMed

46.

van den Bosch T et al. (2010) Genetics of uveal melanoma and cutaneous melanoma: two of a kind? Dermatol Res Pract 2010:360136PubMedPubMedCentral

47.

James AWM et al (2014) Cytogenetics of melanoma: a review. J Assoc Genet Technol 40(4):209–218

48.

Hayward NK et al (2017) Whole-genome landscapes of major melanoma subtypes. Nature 545(7653):175–180PubMedCrossRef

49.

Bastian BC et al (2000) Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin. Cancer Res 60(7):1968–1973PubMed

50.

Furney SJ et al (2014) The mutational burden of acral melanoma revealed by whole-genome sequencing and comparative analysis. Pigment Cell Melanoma Res 27(5):835–838PubMedCrossRef

51.

Kong Y et al (2017) Frequent genetic aberrations in the CDK4 pathway in acral melanoma indicate the potential for CDK4/6 inhibitors in targeted therapy. Clin Cancer Res 23(22):6946–6957PubMedCrossRef

52.

Curtin JA et al (2006) Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24(26):4340–4346PubMedCrossRef

53.

Woodman SE, Davies MA (2010) Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. Biochem Pharmacol 80(5):568–574PubMedPubMedCentralCrossRef

54.

Dumaz N et al (2015) Driver KIT mutations in melanoma cluster in four hotspots. Melanoma Res 25(1):88–90PubMedCrossRef

55.

Fukuda R et al (2001) Gastrointestinal stromal tumor with a novel mutation of KIT proto-oncogene. Intern Med 40(4):301–303PubMedCrossRef

56.

Dai J et al (2013) Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib. Clin Cancer Res 19(24):6935–6942PubMedCrossRef

57.

Board R, Jayson GC (2005) Platelet-derived growth factor receptor (PDGFR): a target for anticancer therapeutics. Drug Resist Update 8(1–2):75–83CrossRef

58.

Haass NK, Herlyn M (2005) Normal human melanocyte homeostasis as a paradigm for understanding melanoma. J Investig Dermatol Symp Proc 10(2):153–163PubMedCrossRef

59.

Yan J et al (2018) Analysis of NRAS gain in 657 patients with melanoma and evaluation of its sensitivity to a MEK inhibitor. Eur J Cancer 89:90–101PubMedCrossRef

60.

Turajlic S et al (2012) Whole genome sequencing of matched primary and metastatic acral melanomas. Genome Res 22(2):196–207PubMedPubMedCentralCrossRef

61.

Diaz A et al (2014) TERT and AURKA gene copy number gains enhance the detection of acral lentiginous melanomas by fluorescence in situ hybridization. J Mol Diagn 16(2):198–206PubMedCrossRef

62.

Liau JY et al (2014) TERT promoter mutation is uncommon in acral lentiginous melanoma. J Cutan Pathol 41(6):504–508PubMedCrossRef

63.

Jovanovic P et al (2013) Ocular melanoma: an overview of the current status. Int J Clin Exp Pathol 6(7):1230–1244PubMedPubMedCentral

64.

Helgadottir H, Hoiom V (2016) The genetics of uveal melanoma: current insights. Appl Clin Genet 9:147–155PubMedPubMedCentralCrossRef

65.

Griewank KG et al (2013) Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas. Clin Cancer Res 19(12):3143–3152PubMedCrossRef

66.

Testa U, Castelli G, Pelosi E (2017) Melanoma: genetic abnormalities, tumor progression, clonal evolution and tumor initiating cells. Med Sci 5(4):28

67.

Van Raamsdonk CD et al (2009) Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457(7229):599–602PubMedCrossRef

68.

Van Raamsdonk CD et al (2010) Mutations in GNA11 in uveal melanoma. New Engl J Med 363(23):2191–2199PubMedCrossRef

69.

Feng X et al (2014) Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Cancer Cell 25(6):831–845PubMedPubMedCentralCrossRef

70.

Moore AR et al (2016) Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma. Nat Genet 48(6):675–680PubMedPubMedCentralCrossRef

71.

Mong S et al (1988) Leukotriene D4 receptor-mediated hydrolysis of phosphoinositide and mobilization of calcium in sheep tracheal smooth muscle cells. J Pharmacol Exp Ther 244(2):508–515PubMed

72.

Johansson P et al (2016) Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4. Oncotarget 7(4):4624–4631CrossRefPubMed

73.

Harbour JW et al (2010) Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330(6009):1410–1413PubMedPubMedCentralCrossRef

74.

Johnson CP et al (2017) Systematic genomic and translational efficiency studies of uveal melanoma. PLoS ONE 12(6):e0178189PubMedPubMedCentralCrossRef

75.

Ismail IH et al (2014) Germline mutations in BAP1 impair its function in DNA double-strand break repair. Cancer Res 74(16):4282–4294CrossRefPubMed

76.

Matatall KA et al (2013) BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma. BMC Cancer 13:371PubMedPubMedCentralCrossRef

77.

Xu J et al (2014) Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma. Cancer Res 74(16):4388–4397PubMedPubMedCentralCrossRef

78.

Martin M et al (2013) Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat Genet 45(8):933–936PubMedPubMedCentralCrossRef

79.

van den Bosch T et al (2012) Higher percentage of FISH-determined monosomy 3 and 8q amplification in uveal melanoma cells relate to poor patient prognosis. Invest Ophthalmol Vis Sci 53(6):2668–2674PubMedCrossRef

80.

de Snoo FA, Hayward NK (2005) Cutaneous melanoma susceptibility and progression genes. Cancer Lett 230(2):153–186PubMedCrossRef

81.

Hussussian CJ et al (1994) Germline p16 mutations in familial melanoma. Nat Genet 8(1):15–21PubMedCrossRef

82.

Zuo L et al (1996) Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 12(1):97–99CrossRefPubMed

83.

Fletcher O et al (2004) Lifetime risks of common cancers among retinoblastoma survivors. J Natl Cancer Inst 96(5):357–363PubMedCrossRef

84.

Wiesner T et al (2011) Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 43(10):1018–1021PubMedPubMedCentralCrossRef

85.

Lin M et al (2017) Common, germline genetic variations in the novel tumor suppressor BAP1 and risk of developing different types of cancer. Oncotarget 8(43):74936–74946PubMedPubMedCentralCrossRef

86.

Aoude LG et al (2015) Genetics of familial melanoma: 20 years after CDKN2A. Pigment Cell Melanoma Res 28(2):148–160PubMedCrossRef

87.

Cronin JC et al (2009) Frequent mutations in the MITF pathway in melanoma. Pigment Cell Melanoma Res 22(4):435–444PubMedPubMedCentralCrossRef

88.

Bertolotto C et al (2011) A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 480(7375):94–98PubMedCrossRef

89.

Yokoyama S et al (2011) A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 480(7375):99–103PubMedPubMedCentralCrossRef

90.

Bertolotto C et al (1998) Microphthalmia gene product as a signal transducer in cAMP-induced differentiation of melanocytes. J Cell Biol 142(3):827–835PubMedPubMedCentralCrossRef

91.

Cao J et al (2013) MC1R is a potent regulator of PTEN after UV exposure in melanocytes. Mol Cell 51(4):409–422PubMedPubMedCentralCrossRef

92.

Vajdic C et al (2003) Ocular melanoma is not associated with CDKN2A or MC1R variants–a population-based study. Melanoma Res 13(4):409–413PubMedCrossRef

93.

Fidler IJ (2011) The pathogenesis of cancer metastasis: the ‘seed and soil’. hypothesis revisited. Int J Cancer 3:453

94.

Bissell M (2011) Why don’t we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med 17(3):320PubMedPubMedCentralCrossRef

95.

Liotta LA (2003) Cancer’s deadly signature. Nat Genet 33:10PubMedCrossRef

96.

Woodhouse EC (1997) General mechanisms of metastasis. Cancer 80:1529PubMedCrossRef

97.

Kabbarah O et al (2010) Integrative genome comparison of primary and metastatic melanomas. PLoS ONE 5(5):e10770PubMedPubMedCentralCrossRef

98.

Natali PG et al (1993) Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression. Br J Cancer 68(4):746–750PubMedPubMedCentralCrossRef

99.

Schmidt H et al (1999) Genomic imbalances of 7p and 17q in malignant peripheral nerve sheath tumors are clinically relevant. Genes Chromosomes Cancer 25(3):205–211PubMedCrossRef

100.

Ubagai T et al (2001) Comparative genomic hybridization analysis suggests a gain of chromosome 7p associated with lymph node metastasis in non-small cell lung cancer. Oncol Rep 8(1):83–88PubMed

101.

Yan J, Huang Q (2012) Genomics screens for metastasis genes. Cancer Metastasis Rev 31(3–4):419–428PubMedPubMedCentralCrossRef

102.

Kim M et al (2006) Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell 125(7):1269–1281PubMedCrossRef

103.

Timar J, Gyorffy B, Raso E (2010) Gene signature of the metastatic potential of cutaneous melanoma: too much for too little? Clin Exp Metastasis 27(6):371–387PubMedCrossRef

104.

Rakosy Z et al (2007) EGFR gene copy number alterations in primary cutaneous malignant melanomas are associated with poor prognosis. Int J Cancer 121(8):1729–1737PubMedCrossRef

105.

Udart M et al (2001) Chromosome 7 aneusomy. A marker for metastatic melanoma? Expression of the epidermal growth factor receptor gene and chromosome 7 aneusomy in nevi, primary malignant melanomas and metastases. Neoplasia 3(3):245–254PubMedPubMedCentralCrossRef

106.

Ding L et al (2014) Clonal architectures and driver mutations in metastatic melanomas. PLoS ONE 9(11):e111153PubMedPubMedCentralCrossRef

107.

Gartner JJ et al (2012) Comparative exome sequencing of metastatic lesions provides insights into the mutational progression of melanoma. BMC Genom 13:505CrossRef

108.

Colombino M et al (2012) BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol 30(20):2522–2529PubMedCrossRef

109.

Jakob JA et al (2012) NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 118(16):4014–4023PubMedCrossRef

110.

Kotani M et al (2001) The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54. J Biol Chem 276(37):34631–34636PubMedCrossRef

111.

Onken MD et al (2012) Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology 119(8):1596–1603PubMedCrossRef

112.

Field MG et al (2018) Punctuated evolution of canonical genomic aberrations in uveal melanoma. Nat Commun 9(1):116PubMedPubMedCentralCrossRef

113.

Bakalian S et al (2008) Molecular pathways mediating liver metastasis in patients with uveal melanoma. Clin Cancer Res 14(4):951–956PubMedCrossRef

114.

Hu M (2008) Regulation of in situ to invasive breast carcinoma transition. Cancer Cell 13(5):394PubMedPubMedCentralCrossRef

115.

Giampieri S (2009) Localized and reversible TGFβ signaling switches breast cancer cells from cohesive to single cell motility. Nat Cell Biol 11:1287PubMedPubMedCentralCrossRef

116.

Padua D (2008) TGF-beta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 133(1):66PubMedPubMedCentralCrossRef

117.

Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584PubMedCrossRef

118.

Logothetis CJ (2005) Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 5(1):21PubMedCrossRef

119.

Kang Y (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3:537CrossRefPubMed

120.

Sethi N (2011) Tumor-derived jagged1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell 19(2):192PubMedPubMedCentralCrossRef

121.

Kang Y (2005) Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci USA 102(39):13909PubMedCrossRefPubMedCentral

122.

Yin JJ (1999) TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 103:197PubMedPubMedCentralCrossRef

123.

Minn AJ (2005) Genes that mediate breast cancer metastasis to lung. Nature 436: 518PubMedPubMedCentralCrossRef

124.

Gupta GP (2006) Cancer metastasis: building a framework. Cell 127(4):679CrossRefPubMed

125.

Luo JL (2004) Inhibition of NF-kappaB in cancer cells converts inflammation-induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell 6:297PubMedCrossRef

126.

Siegel PM (2003) Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci USA 100(14):8430PubMedCrossRefPubMedCentral

127.

Davidson B (2004) Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumour progression. Clin Cancer Res 10(21):7335PubMedCrossRef

128.

Hess KR (2006) Metastatic patterns in adenocarcinoma. Cancer 106(7):1624PubMedCrossRef

129.

Tabariès S (2011) Claudin-2 is selectively enriched in and promotes the formation of breast cancer liver metastases through engagement of integrin complexes. Oncogene 32:1318CrossRef

130.

Winquist E (2006) Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care’s Genitourinary Cancer Disease Site Group. BMC Cancer 6:112PubMedPubMedCentralCrossRef

131.

Bubendorf L (2000) Metastatic patterns of prostate cancer: an autopsy study of 1589 patients. Hum Pathol 31(5):578CrossRefPubMed

132.

Mimeault M (2011) Frequent gene products and molecular pathways altered in prostate cancer- and metastasis-initiating cells and their progenies and novel promising multitargeted therapies. Mol Med 17:9CrossRef

133.

Mimeault M (2006) Functions of normal and malignant prostatic stem/progenitor cells in tissue regeneration and cancer progression and novel targeting therapies. Carcinogenesis 27(1):1PubMedCrossRef

134.

Mimeault M (2008) Prospective identification of tumorigenic prostate cancer stem cells. Endocr Rev 29(2):234PubMedPubMedCentralCrossRef

135.

Harada S (2003) Control of osteoblast function and regulation of bone mass. Nature 423:349PubMedCrossRef

136.

Faltermeier C (2016) Functional screen identifies kinases driving prostate cancer visceral and bone metastasis. Proc Natl Acad Sci USA 113(2):E172PubMedCrossRef

137.

Siegel RL (2015) Cancer statistics. CA: Cancer J Clin 65(1):5

138.

Nguyen DX (2009) Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 9:274PubMedCrossRef

139.

Popper HH (2016) Progression and metastasis of lung cancer. Caner Metastasis Rev 35:75CrossRef

140.

Yang J (2004) Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117(7):927CrossRefPubMed

141.

Xie L (2013) Genome-wide identification of bone metastasis-related microRNAs in lung adenocarcinoma by high-throughput sequencing. PLoS ONE 8(4):e61212PubMedPubMedCentralCrossRef

142.

Rao S (2017) RANK requires energy homoeostasis in lung cancer cells and drives primary lung cancer. Genes 31(20):2099CrossRef

143.

Vicent S (2008) A novel lung cancer signature mediates metastatic bone colonization by a dual mechanism. Can Res 68(7):2275CrossRef

144.

Preusser M (2014) High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer. Lung Cancer 83(1):83PubMedCrossRef

145.

Pukrop T (2010) Microglia promote colonization of brain tissue by breast cancer cells in a Wnt-dependent way. Glia 58(12):1477PubMedCrossRef

146.

Wang L (2013) Astrocytes directly influence tumor cell invasion and metastasis in vivo. PLoS ONE 8(12):e80933PubMedPubMedCentralCrossRef

147.

Qiu M et al. (2015) Pattern of distant metastases in colorectal cancer: a SEER based study. Oncotarget 6:38658–38666PubMedPubMedCentralCrossRef

148.

Cook AD (2005) Surgical resection of primary tumors in patients who present with stage IV colorectal cancer: an analysis of surveillance, epidemiology, and end results data, 1988 to 2000. Ann Sure Oncol 12(8):637CrossRef

149.

Sun L (2011) P-cadherin promotes liver metastasis and is associated with poor prognosis in colon cancer. Am J Pathol 179(1):380PubMedPubMedCentralCrossRef

150.

Hansen IO (2012) Possible better long-term survival in left versus right-sided colon cancer: a systematic review. Dan Med J 59(6):A4444PubMed

151.

Benedix F (2010) Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum 53(1):57CrossRefPubMed

152.

Iino H (1994) Molecular genetics for clinical management of colorectal carcinoma. 17p, 18q, and 22q loss of heterozygosity and decreased DCC expression are correlated with the metastatic potential. Cancer 73(5):1324PubMedCrossRef

153.

Ookawa K (1993) Concordant p53 and DCC alterations and allelic losses on chromosomes 13q and 14q associated with liver metastases of colorectal carcinoma. Cancer 53(3):382

154.

Kemler R (1993) From cadherins to catenins: cytoplasmic protein interactions and regulation of cell adhesion. Trends Genet 9(9):317PubMedCrossRef

155.

Dolled-Filhart M (2006) Quantitative in situ analysis of β-catenin expression in breast cancer shows decreased expression is associated with poor outcome. Can Res 66(10):5487CrossRef

156.

Chao Y (2014) Hepatocyte induced re-expression of E-cadherin in breast and prostate cancer cells increases chemoresistance. Clin Exp Metastasis 29(1):39CrossRef

157.

Adams GN (2015) Colon cancer growth and dissemination relies upon thrombin, stromal PAR-1, and fibrinogen. Can Res 75(19):4235CrossRef

158.

Turajlic S, Swanton C (2016) Metastasis as an evolutionary process. Science 352(6282):169–175PubMedCrossRef

159.

Negrini S, Gorgoulis VG, Halazonetis TD (2010) Genomic instability: an evolving hallmark of cancer. Nat Rev Mol Cell Biol 11(3):220–228PubMedCrossRef

160.

Brannon AR et al (2014) Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome Biol 15(8):454PubMedPubMedCentralCrossRef

161.

Martincorena I et al (2015) Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science 348(6237):880–886PubMedPubMedCentralCrossRef

162.

Sanborn JZ et al (2015) Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination. Proc Natl Acad Sci USA 112(35):10995–11000PubMedCrossRefPubMedCentral

163.

Bissell MJ, Hines WC (2011) Why don’t we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med 17(3):320–329PubMedPubMedCentralCrossRef

164.

Park YJ (2011) Genome-wide epigenetic modifications in cancer. Progress Drug Res 67:25–49

165.

Metri R et al (2017) Identification of a gene signature for discriminating metastatic from primary melanoma using a molecular interaction network approach. Sci Rep 7(1):17314PubMedPubMedCentralCrossRef

166.

Shen SS et al (2003) Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array. J Cutan Pathol 30(9):539–547PubMedCrossRef

167.

Isabel Zhu Y, Fitzpatrick JE (2006) Expression of c-kit (CD117) in Spitz nevus and malignant melanoma. J Cutan Pathol 33(1):33–37PubMedCrossRef

168.

Del C Velasco-Herrera M et al (2017) Comparative genomics reveals that loss of lunatic fringe (LFNG) promotes melanoma metastasis. Mol Oncol 12(2):239–255CrossRef

169.

Lian CG et al (2012) Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 150(6):1135–1146PubMedPubMedCentralCrossRef

170.

Boissan M, Lacombe ML (2012) NM23, an example of a metastasis suppressor gene. Bull Cancer 99(4):431–440PubMedCrossRef

171.

Clark EA et al (2000) Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406(6795):532–535PubMedCrossRef

172.

Li J et al (2011) Prognostic significance of BRMS1 expression in human melanoma and its role in tumor angiogenesis. Oncogene 30(8):896–906PubMedCrossRef

173.

Achyut BR (2013) Inflammation-mediated genetic and epigenetic alterations drive cancer development in the neighboring epithelium upon stromal abrogation of TGF-β signaling. PLoS Genet 9(2):e1003251PubMedPubMedCentralCrossRef

174.

Pogribny IP (2013) DNA methylome alterations in chemical carcinogenesis. Cancer Lett 334(1):39PubMedCrossRef

175.

Gould CM (2014) Regulation of invadopodia by the tumor microenvironment. Cell Adhes Migr 8(3):226CrossRef

176.

Weber CE (2012) The tumor microenvironment. Surg Oncol 21(3):172PubMedCrossRef

177.

Zamarron BF (2011) Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci 7(5):651PubMedPubMedCentralCrossRef

178.

Spaeth E (2008) Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther 15(10):730PubMedCrossRef

179.

Hanahan D (2011) Hallmarks of cancer: the next generation. Cell 144(5):646PubMedCrossRef

Title: Genetics of metastasis: melanoma and other cancers
Authors: Noel Turner
Olivia Ware
Marcus Bosenberg
Publication date: 01-08-2018
Publisher: Springer Netherlands
Published in: Clinical & Experimental Metastasis / Issue 5-6/2018
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-018-9893-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

ACC 2024 Congress

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5-6/2018

Alternative splicing and cancer metastasis: prognostic and therapeutic applications

Editorial

Lymphedema following cancer therapy: overview and options

Cystatin C takes part in melanoma-microglia cross-talk: possible implications for brain metastasis

Cancer initiation and progression within the cancer microenvironment

Review of diagnostic, prognostic, and predictive biomarkers in melanoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer